^
    over1year
    A mesothelin targeting chimeric antigen receptor macrophage (CAR-M) for solid tumor immunotherapy: pre-clinical development of CT-1119 (AACR 2023)
    We have previously developed CT-0508, a chimeric antigen receptor macrophage (CAR-M) targeting HER2 which showed efficacy in a variety of pre-clinical models and is currently in a Phase I clinical trial for patients with HER2+ solid tumors. The presented results demonstrate that CT-1119, an autologous human anti-mesothelin CAR-M, can cause phagocytosis, tumor cell killing, and pro-inflammatory cytokine release in response to stimulation with mesothelin. These results show that CAR-M is a feasible approach for the treatment of mesothelin expressing sold tumors via the potential for induction of a systemic anti-tumor response.
    Preclinical • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSLN (Mesothelin) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    HER-2 overexpression • MSLN expression • MSLN overexpression • MSLN positive
    |
    CT-0508 • CT-1119
    2years
    Pre-clinical development of CT-1119, a mesothelin targeting chimeric antigen receptor macrophage (CAR-M), for solid tumor immunotherapy (SITC 2022)
    Conclusions The presented results demonstrate that CT-1119, an autologous human anti-mesothelin CAR-M, can cause phagocytosis, tumor cell killing, and pro-inflammatory cytokine release in response to stimulation with mesothelin. These results show that CAR-M is a feasible approach for the treatment of mesothelin expressing sold tumors via the potential for induction of a systemic anti-tumor response.
    Preclinical • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • MSLN (Mesothelin) • TNFA (Tumor Necrosis Factor-Alpha)
    |
    MSLN expression • MSLN overexpression • MSLN positive
    |
    CT-1119